Case Studies

CRISPR-Based SARS-CoV-2 Saliva Test

Wainamics was chosen for this Innovative Genomics Institute project in collaboration with Jennifer Doudna, Patrick Hsu, David Savage and Dan Fletcher at UC Berkeley to provide expertise in microfluidic cartridge design and system development of multiple CRISPR point-of-care testing systems for high sensitivity, rapid testing of SARS-CoV-2.

We optimized the cartridge design for multiplexing, enabling rapid test with 94% sensitivity and 100% specificity when validated against quantitative PCR.

Testimonials

  • — Parag Mallick, Professor at Stanford, Co-founder and CSO
    "Early in our journey Wainamics was a critical partner in getting us on the fast track to product development. Their deep expertise in microfluidic cartridge design, system architecture and material selection helped us rapidly explore possible options and move beyond ideation into the assay development required to hit our milestones. I highly recommend them!"
    — Parag Mallick, Professor at Stanford, Co-founder and CSO

How can we help you with your project? Let's talk.

    New Location:

    492 Division Street

    Campbell, CA 95008

    • 2014Wainamics Incorporation

    • 2015First Patent on Blood Separation

    • 2017Factor VIII Coagulation Platform

    • 2018Move to Pleasanton, CA

      2000 sqft lab
    • 2019Ignite $27m Series A

    • 2020Molecular Test Platform

      $2m RADx funding and AmplifiDx Spinoff
    • 2021Collaboration with Jennifer Doudna at IGI

      $2m RADx funding and AmplifiDx Spinoff
    • 2021Move to 7026 Koll Center

      4000 sqft
    • 2023NASA SBIR Phase I & II, $1m

      Cell Perfusion System
    • 2023PCR STD Chip

    • 202410th Year Anniversary

      100+ Projects     |     50+ Companies
    • 2025New Location Coming Soon!

      We will be moving to a larger facility. More details to come.